{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:59:46Z","timestamp":1780775986709,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijcha.2026.101908","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:26:43Z","timestamp":1776299203000},"page":"101908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9121-2217","authenticated-orcid":false,"given":"Muhammad","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husna Irfan","family":"Thalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Bin","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Adil","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaraja","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Muddassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Parker","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Albaghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ijcha.2026.101908_b0005","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ijcha.2026.101908_b0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11886-020-01381-3","article-title":"Hypertrophic Cardiomyopathy 2020","volume":"22","author":"Kogut","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"35","key":"10.1016\/j.ijcha.2026.101908_b0015","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.ijcha.2026.101908_b0020","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/psp4.13197","article-title":"Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration","volume":"13","author":"Chang","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"10253","key":"10.1016\/j.ijcha.2026.101908_b0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ijcha.2026.101908_b0030","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic patients with Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2026.101908_b0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11897-023-00620-2","article-title":"Differentiating Cardiac Troponin Levels during Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug effect or the Canary in the Coal Mine?","volume":"20","author":"Lee","year":"2023","journal-title":"Curr. Heart Fail. Rep."},{"issue":"2","key":"10.1016\/j.ijcha.2026.101908_b0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics ofODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail."},{"issue":"25","key":"10.1016\/j.ijcha.2026.101908_b0045","first-page":"07460","article-title":"ODYSSEY-HCM Investigators. Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial","volume":"S0735\u20131097","author":"Desai","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2026.101908_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s44348-025-00052-7","article-title":"Cardiac myosin inhibitors in hypertrophic cardiomyopathy","volume":"33","author":"Lim","year":"2025","journal-title":"J Cardiovasc Imaging."},{"issue":"6","key":"10.1016\/j.ijcha.2026.101908_b0055","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2015.06.018","article-title":"Comparison of Outcomes in patients with Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy","volume":"116","author":"Pozios","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcha.2026.101908_b0060","first-page":"531","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC","volume":"10","author":"Nassif","year":"2022","journal-title":"Heart Failure."},{"issue":"10","key":"10.1016\/j.ijcha.2026.101908_b0065","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ijcha.2026.101908_b0070","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.112.113233","article-title":"Diastolic Dysfunction and risk of Atrial Fibrillation","volume":"126","author":"Rosenberg","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcha.2026.101908_b0075","first-page":"672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart Br Card Soc."},{"key":"10.1016\/j.ijcha.2026.101908_b0080","article-title":"Intensification of monitoring for improving detection of atrial fibrillation after a presumed \u201ctrigger- induced episode\u201d due to potentially reversible factors: what tools and what implications for decision making?","volume":"106660","author":"Boriani","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcha.2026.101908_b0085","unstructured":"B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy | JACC [Internet]. [cited 2025 Apr 5]. Available from: https:\/\/www.jacc.org\/doi\/abs\/10.1016\/j.jacc.2013.04.004."},{"issue":"24","key":"10.1016\/j.ijcha.2026.101908_b0090","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"JACC"},{"key":"10.1016\/j.ijcha.2026.101908_b0095","unstructured":"Significance of High-Sensitivity Cardiac Troponin T in Hypertrophic Cardiomyopathy | JACC [Internet]. [cited 2025 Apr 5]. Available from: https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2013.03.055."},{"key":"10.1016\/j.ijcha.2026.101908_b0100","unstructured":"Serum Levels of High-Sensitivity Troponin T: A Novel Marker for Cardiac Remodeling in Hypertrophic Cardiomyopathy - Journal of Cardiac Failure [Internet]. [cited 2025 Apr 5]. Available from: https:\/\/onlinejcf.com\/article\/S1071-9164(10)00960-7\/abstract."},{"issue":"14","key":"10.1016\/j.ijcha.2026.101908_b0105","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","article-title":"Significance of High-Sensitivity Cardiac Troponin T in Hypertrophic Cardiomyopathy","volume":"62","author":"Kubo","year":"2013","journal-title":"JACC"},{"issue":"6","key":"10.1016\/j.ijcha.2026.101908_b0110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of High-Sensitivity Cardiac Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in patients with Hypertrophic Cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcha.2026.101908_b0115","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic Value of LGE-CMR in HCM","volume":"9","author":"Weng","year":"2016","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"8","key":"10.1016\/j.ijcha.2026.101908_b0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late Gadolinium Enhancement in patients with Hypertrophic Cardiomyopathy and Preserved Systolic Function","volume":"72","author":"Mentias","year":"2018","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.ijcha.2026.101908_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102564","article-title":"Body Mass Index, Left Ventricular Wall stress, and NT-proBNP in elderly adults","volume":"5","author":"White","year":"2026","journal-title":"JACC Adv."},{"issue":"2","key":"10.1016\/j.ijcha.2026.101908_b0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/cpt.2222","article-title":"NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart failure","volume":"110","author":"Schmitt","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ijcha.2026.101908_b0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ehjci\/jey135","article-title":"Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications","volume":"20","author":"Raman","year":"2019","journal-title":"Eur Heart J - Cardiovasc Imaging."},{"issue":"12","key":"10.1016\/j.ijcha.2026.101908_b0140","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary Natural history and Management of Nonobstructive Hypertrophic Cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"JACC"},{"issue":"11","key":"10.1016\/j.ijcha.2026.101908_b0145","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/hrt.35.11.1116","article-title":"Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy","volume":"35","author":"Hubner","year":"1973","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ijcha.2026.101908_b0150","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2026.101908_b0155","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjcard.2023.10.074","article-title":"Medical Treatment strategies for Hypertrophic Cardiomyopathy","volume":"212","author":"Hutt","year":"2024","journal-title":"Am. J. Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906726000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906726000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:23:41Z","timestamp":1780773821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906726000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S2352906726000424"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2026.101908","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2026.101908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101908"}}